South Korea-based Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has signed a supply agreement with Raffles Medical for its neurodegenerative brain imaging analysis software, Neurophet AQUA.
Neurophet AQUA is a neurodegenerative brain imaging analysis software that performs ultra-fast quantitative analysis of patients' brain MRI scans, enabling the assessment of brain atrophy and white matter degeneration. It quantifies structural changes in the brain—such as atrophy and white matter alterations—observed in neurodegenerative diseases including Alzheimer's disease and vascular dementia, and delivers customized analysis reports tailored to individual patients.
Raffles Medical is the primary healthcare arm of Raffles Medical Group, operating a network of more than 100 multi-disciplinary clinics across Singapore and Asia. The clinic network is integrated with Raffles Hospital and Raffles Specialist Centres, providing patients with access to specialist and diagnostic services.
